View More Recent Stories

Oct 25, 2024 08:06AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 25, 2024 05:52AM CapitalOne Reiterates Underweight Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 24, 2024 02:34PM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 24, 2024 07:02AM EyePoint Pharmaceuticals (EYPT) Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024 07:01AM EyePoint Pharmaceuticals (EYPT) Appoints Fred Hassan to its Board

Aug 28, 2024 02:16AM Jefferies Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy

Aug 7, 2024 07:07AM EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c

Jun 27, 2024 12:30PM TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Jun 27, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Jun 26, 2024 03:45PM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Jun 26, 2024 08:01AM EyePoint Pharmaceuticals (EYPT) to Highlight DURAVYUTM Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

View More Recent Stories